about

  A scientist by trade, Adam has a PhD in cancer biology from Oxford University and a executive MBA from Edinburgh. After a decade in R&D at AstraZeneca, Applied Biosystems & Lab901, Adam has spent the last 15 years in marketing & commercial roles developing market and product strategy for the likes of Agilent, Merck-BioReliance & Symbiosis.

With over 50 research publications and more than £7million in grant funding, John has built enormous academic and practical expertise in lentivirus vector design and production for clinical applications.  John established and directs the molecular interventions research group in the UCL Division of Surgery, a team developing gene therapy technologies for diseases with a severe unmet need.

Michael has an impressive background in industrial biotechnology, bringing substantial fundraising and business development expertise as well as a detailed understanding of licensing & IP. Having held various board and senior leadership positions over the last two decades, Michael pioneered the industrialisation of synthetic promoter design with Edinburgh based Synpromics, which he founded in 2010. Synpromics was acquired by AskBio in 2019.

Dave has been involved with the contract manufacturing of viral vectors since the late 90’s, where he led the pioneering Molecular Medicine BioServices company through a management buyout and then sale to Sigma-Aldrich.  Having held various posts, including with Oxford Biomedica as CCO, Dave is currently CEO of Curate Biosciences, a CAR-T manufacturing hardware company.

  A senior leader in technology and life science industries with a broad range of experience across both start up, SMEs and large multinational technology companies.  Currently CTO at Reactec Ltd, a safety tech IoT business and an active angel investor, Leif has helped both establish Lentitek and guide it throughout its journey.

Andy is an investor and advisor in new science and technology ventures, with 30 years’ experience in IT, business development, strategy and partnerships. Since selling his last venture in 2015, Andy has been an active member of the Scottish entrepreneurial ecosystem and supports a number of high-growth companies at from Pre-seed to Series A stages.